Personalising pancreas cancer treatment:When tissue is the issue
The treatment of advanced pancreatic cancer has not moved much beyond single agent gemcitabine until recently when protocols such as FOLFIRINOX(fluorouracil,leucovorin,irinotecan and oxaliplatin)and nab-paclitaxelgemcitabine have demonstrated some improved outcomes.Advances in technology especially...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG 2014-06, Vol.20 (24), p.7849-7863 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7863 |
|---|---|
| container_issue | 24 |
| container_start_page | 7849 |
| container_title | World journal of gastroenterology : WJG |
| container_volume | 20 |
| creator | Sjoquist, Katrin M Chin, Venessa T Chantrill, Lorraine A O'Connor, Chelsie Hemmings, Chris Chang, David K Chou, Angela Pajic, Marina Johns, Amber L Nagrial, Adnan M Biankin, Andrew V Yip, Desmond |
| description | The treatment of advanced pancreatic cancer has not moved much beyond single agent gemcitabine until recently when protocols such as FOLFIRINOX(fluorouracil,leucovorin,irinotecan and oxaliplatin)and nab-paclitaxelgemcitabine have demonstrated some improved outcomes.Advances in technology especially in massively parallel genome sequencing has progressed our understanding of the biology of pancreatic cancer especially the candidate signalling pathways that are involved in tumourogenesis and disease course.This has allowed identification of potentially actionable mutations that may be targeted by new biological agents.The heterogeneity of pancreatic cancer makes tumour tissue collection important with the aim of being able to personalise therapies for the individual as opposed to a one size fits all approach to treatment of the condition.This paper reviews the developments in this area of translational research and the ongoing clinical studies that will attempt to move this into the everyday oncology practice. |
| doi_str_mv | 10.3748/wjg.v20.i24.7849 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4069313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>90888889504849525052485149</cqvip_id><sourcerecordid>1552372110</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-f5b254bce8f03e8217eee1c770e053b201d2e7c289bb0f0e82c75766ea33fc133</originalsourceid><addsrcrecordid>eNpVkD1PwzAQhi0EgvKxM6GMLCnns10nDAhU8SUhwQBitBxzaY3SpNgpiH-PC6UCL-eT33t8ehg75DAUWhYnH6-T4TvC0KMc6kKWG2yAyMscCwmbbMABdF4K1DtsN8ZXABRC4TbbQVnqkUYcsPMHCrFrbeOjbyfZ3LYukI2ZSxcKWZ-afkZtf_o8pTbrfYwLynzM-umypGafbdW2iXSwqnvs6erycXyT391f344v7nInJfR5rSpUsnJU1CCoQK6JiDutgUCJCoG_IGmHRVlVUENKOK30aERWiNpxIfbY2Q93vqhm9OLSTsE2Zh78zIZP01lv_r-0fmom3buRMCrFN-B4BQjd24Jib2Y-Omoa21K3iIYrhUIj55Ci8BN1oYsxUL3-hoNZijdJvEniTRJvluLTyNHf9dYDv6ZTQKyY066dvCXZ60wJxfKUCmRCKVSgUBaKJ-wXMzWQhQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1552372110</pqid></control><display><type>article</type><title>Personalising pancreas cancer treatment:When tissue is the issue</title><source>MEDLINE</source><source>Baishideng "World Journal of" online journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Sjoquist, Katrin M ; Chin, Venessa T ; Chantrill, Lorraine A ; O'Connor, Chelsie ; Hemmings, Chris ; Chang, David K ; Chou, Angela ; Pajic, Marina ; Johns, Amber L ; Nagrial, Adnan M ; Biankin, Andrew V ; Yip, Desmond</creator><creatorcontrib>Sjoquist, Katrin M ; Chin, Venessa T ; Chantrill, Lorraine A ; O'Connor, Chelsie ; Hemmings, Chris ; Chang, David K ; Chou, Angela ; Pajic, Marina ; Johns, Amber L ; Nagrial, Adnan M ; Biankin, Andrew V ; Yip, Desmond</creatorcontrib><description>The treatment of advanced pancreatic cancer has not moved much beyond single agent gemcitabine until recently when protocols such as FOLFIRINOX(fluorouracil,leucovorin,irinotecan and oxaliplatin)and nab-paclitaxelgemcitabine have demonstrated some improved outcomes.Advances in technology especially in massively parallel genome sequencing has progressed our understanding of the biology of pancreatic cancer especially the candidate signalling pathways that are involved in tumourogenesis and disease course.This has allowed identification of potentially actionable mutations that may be targeted by new biological agents.The heterogeneity of pancreatic cancer makes tumour tissue collection important with the aim of being able to personalise therapies for the individual as opposed to a one size fits all approach to treatment of the condition.This paper reviews the developments in this area of translational research and the ongoing clinical studies that will attempt to move this into the everyday oncology practice.</description><identifier>ISSN: 1007-9327</identifier><identifier>ISSN: 2219-2840</identifier><identifier>EISSN: 2219-2840</identifier><identifier>DOI: 10.3748/wjg.v20.i24.7849</identifier><identifier>PMID: 24976722</identifier><language>eng</language><publisher>United States: Baishideng Publishing Group Inc</publisher><subject>Animals ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers, Tumor - genetics ; DNA Mutational Analysis ; Drug Design ; Genetic Predisposition to Disease ; Genetic Testing - methods ; Humans ; Molecular ; Molecular Targeted Therapy ; Mutation ; neoplasms ; Pancreatic ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - genetics ; Pancreatic Neoplasms - pathology ; Patient Selection ; Phenotype ; Precision Medicine ; Predictive Value of Tests ; Signal Transduction - drug effects ; Signal Transduction - genetics ; targeted ; therapy ; Topic Highlight</subject><ispartof>World journal of gastroenterology : WJG, 2014-06, Vol.20 (24), p.7849-7863</ispartof><rights>2014 Baishideng Publishing Group Inc. All rights reserved. 2014</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-f5b254bce8f03e8217eee1c770e053b201d2e7c289bb0f0e82c75766ea33fc133</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/84123X/84123X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069313/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069313/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24976722$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sjoquist, Katrin M</creatorcontrib><creatorcontrib>Chin, Venessa T</creatorcontrib><creatorcontrib>Chantrill, Lorraine A</creatorcontrib><creatorcontrib>O'Connor, Chelsie</creatorcontrib><creatorcontrib>Hemmings, Chris</creatorcontrib><creatorcontrib>Chang, David K</creatorcontrib><creatorcontrib>Chou, Angela</creatorcontrib><creatorcontrib>Pajic, Marina</creatorcontrib><creatorcontrib>Johns, Amber L</creatorcontrib><creatorcontrib>Nagrial, Adnan M</creatorcontrib><creatorcontrib>Biankin, Andrew V</creatorcontrib><creatorcontrib>Yip, Desmond</creatorcontrib><title>Personalising pancreas cancer treatment:When tissue is the issue</title><title>World journal of gastroenterology : WJG</title><addtitle>World Journal of Gastroenterology</addtitle><description>The treatment of advanced pancreatic cancer has not moved much beyond single agent gemcitabine until recently when protocols such as FOLFIRINOX(fluorouracil,leucovorin,irinotecan and oxaliplatin)and nab-paclitaxelgemcitabine have demonstrated some improved outcomes.Advances in technology especially in massively parallel genome sequencing has progressed our understanding of the biology of pancreatic cancer especially the candidate signalling pathways that are involved in tumourogenesis and disease course.This has allowed identification of potentially actionable mutations that may be targeted by new biological agents.The heterogeneity of pancreatic cancer makes tumour tissue collection important with the aim of being able to personalise therapies for the individual as opposed to a one size fits all approach to treatment of the condition.This paper reviews the developments in this area of translational research and the ongoing clinical studies that will attempt to move this into the everyday oncology practice.</description><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers, Tumor - genetics</subject><subject>DNA Mutational Analysis</subject><subject>Drug Design</subject><subject>Genetic Predisposition to Disease</subject><subject>Genetic Testing - methods</subject><subject>Humans</subject><subject>Molecular</subject><subject>Molecular Targeted Therapy</subject><subject>Mutation</subject><subject>neoplasms</subject><subject>Pancreatic</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - genetics</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Patient Selection</subject><subject>Phenotype</subject><subject>Precision Medicine</subject><subject>Predictive Value of Tests</subject><subject>Signal Transduction - drug effects</subject><subject>Signal Transduction - genetics</subject><subject>targeted</subject><subject>therapy</subject><subject>Topic Highlight</subject><issn>1007-9327</issn><issn>2219-2840</issn><issn>2219-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkD1PwzAQhi0EgvKxM6GMLCnns10nDAhU8SUhwQBitBxzaY3SpNgpiH-PC6UCL-eT33t8ehg75DAUWhYnH6-T4TvC0KMc6kKWG2yAyMscCwmbbMABdF4K1DtsN8ZXABRC4TbbQVnqkUYcsPMHCrFrbeOjbyfZ3LYukI2ZSxcKWZ-afkZtf_o8pTbrfYwLynzM-umypGafbdW2iXSwqnvs6erycXyT391f344v7nInJfR5rSpUsnJU1CCoQK6JiDutgUCJCoG_IGmHRVlVUENKOK30aERWiNpxIfbY2Q93vqhm9OLSTsE2Zh78zIZP01lv_r-0fmom3buRMCrFN-B4BQjd24Jib2Y-Omoa21K3iIYrhUIj55Ci8BN1oYsxUL3-hoNZijdJvEniTRJvluLTyNHf9dYDv6ZTQKyY066dvCXZ60wJxfKUCmRCKVSgUBaKJ-wXMzWQhQ</recordid><startdate>20140628</startdate><enddate>20140628</enddate><creator>Sjoquist, Katrin M</creator><creator>Chin, Venessa T</creator><creator>Chantrill, Lorraine A</creator><creator>O'Connor, Chelsie</creator><creator>Hemmings, Chris</creator><creator>Chang, David K</creator><creator>Chou, Angela</creator><creator>Pajic, Marina</creator><creator>Johns, Amber L</creator><creator>Nagrial, Adnan M</creator><creator>Biankin, Andrew V</creator><creator>Yip, Desmond</creator><general>Baishideng Publishing Group Inc</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140628</creationdate><title>Personalising pancreas cancer treatment:When tissue is the issue</title><author>Sjoquist, Katrin M ; Chin, Venessa T ; Chantrill, Lorraine A ; O'Connor, Chelsie ; Hemmings, Chris ; Chang, David K ; Chou, Angela ; Pajic, Marina ; Johns, Amber L ; Nagrial, Adnan M ; Biankin, Andrew V ; Yip, Desmond</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-f5b254bce8f03e8217eee1c770e053b201d2e7c289bb0f0e82c75766ea33fc133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers, Tumor - genetics</topic><topic>DNA Mutational Analysis</topic><topic>Drug Design</topic><topic>Genetic Predisposition to Disease</topic><topic>Genetic Testing - methods</topic><topic>Humans</topic><topic>Molecular</topic><topic>Molecular Targeted Therapy</topic><topic>Mutation</topic><topic>neoplasms</topic><topic>Pancreatic</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - genetics</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Patient Selection</topic><topic>Phenotype</topic><topic>Precision Medicine</topic><topic>Predictive Value of Tests</topic><topic>Signal Transduction - drug effects</topic><topic>Signal Transduction - genetics</topic><topic>targeted</topic><topic>therapy</topic><topic>Topic Highlight</topic><toplevel>online_resources</toplevel><creatorcontrib>Sjoquist, Katrin M</creatorcontrib><creatorcontrib>Chin, Venessa T</creatorcontrib><creatorcontrib>Chantrill, Lorraine A</creatorcontrib><creatorcontrib>O'Connor, Chelsie</creatorcontrib><creatorcontrib>Hemmings, Chris</creatorcontrib><creatorcontrib>Chang, David K</creatorcontrib><creatorcontrib>Chou, Angela</creatorcontrib><creatorcontrib>Pajic, Marina</creatorcontrib><creatorcontrib>Johns, Amber L</creatorcontrib><creatorcontrib>Nagrial, Adnan M</creatorcontrib><creatorcontrib>Biankin, Andrew V</creatorcontrib><creatorcontrib>Yip, Desmond</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sjoquist, Katrin M</au><au>Chin, Venessa T</au><au>Chantrill, Lorraine A</au><au>O'Connor, Chelsie</au><au>Hemmings, Chris</au><au>Chang, David K</au><au>Chou, Angela</au><au>Pajic, Marina</au><au>Johns, Amber L</au><au>Nagrial, Adnan M</au><au>Biankin, Andrew V</au><au>Yip, Desmond</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Personalising pancreas cancer treatment:When tissue is the issue</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World Journal of Gastroenterology</addtitle><date>2014-06-28</date><risdate>2014</risdate><volume>20</volume><issue>24</issue><spage>7849</spage><epage>7863</epage><pages>7849-7863</pages><issn>1007-9327</issn><issn>2219-2840</issn><eissn>2219-2840</eissn><abstract>The treatment of advanced pancreatic cancer has not moved much beyond single agent gemcitabine until recently when protocols such as FOLFIRINOX(fluorouracil,leucovorin,irinotecan and oxaliplatin)and nab-paclitaxelgemcitabine have demonstrated some improved outcomes.Advances in technology especially in massively parallel genome sequencing has progressed our understanding of the biology of pancreatic cancer especially the candidate signalling pathways that are involved in tumourogenesis and disease course.This has allowed identification of potentially actionable mutations that may be targeted by new biological agents.The heterogeneity of pancreatic cancer makes tumour tissue collection important with the aim of being able to personalise therapies for the individual as opposed to a one size fits all approach to treatment of the condition.This paper reviews the developments in this area of translational research and the ongoing clinical studies that will attempt to move this into the everyday oncology practice.</abstract><cop>United States</cop><pub>Baishideng Publishing Group Inc</pub><pmid>24976722</pmid><doi>10.3748/wjg.v20.i24.7849</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1007-9327 |
| ispartof | World journal of gastroenterology : WJG, 2014-06, Vol.20 (24), p.7849-7863 |
| issn | 1007-9327 2219-2840 2219-2840 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4069313 |
| source | MEDLINE; Baishideng "World Journal of" online journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Animals Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor - genetics DNA Mutational Analysis Drug Design Genetic Predisposition to Disease Genetic Testing - methods Humans Molecular Molecular Targeted Therapy Mutation neoplasms Pancreatic Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Pancreatic Neoplasms - pathology Patient Selection Phenotype Precision Medicine Predictive Value of Tests Signal Transduction - drug effects Signal Transduction - genetics targeted therapy Topic Highlight |
| title | Personalising pancreas cancer treatment:When tissue is the issue |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T06%3A08%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Personalising%20pancreas%20cancer%20treatment:When%20tissue%20is%20the%20issue&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=Sjoquist,%20Katrin%20M&rft.date=2014-06-28&rft.volume=20&rft.issue=24&rft.spage=7849&rft.epage=7863&rft.pages=7849-7863&rft.issn=1007-9327&rft.eissn=2219-2840&rft_id=info:doi/10.3748/wjg.v20.i24.7849&rft_dat=%3Cproquest_pubme%3E1552372110%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1552372110&rft_id=info:pmid/24976722&rft_cqvip_id=90888889504849525052485149&rfr_iscdi=true |